Not All Lutetium Ticks the Same Clock: Disease-Specific Optimization of Post-Treatment SPECT/CT Timing in 177 Lu Theranostics (EANM 2026) - Sep 29, 2026 - Abstract #OP-622; Pres time: Oct 20, 2026; 09:45 AM - 11:15 AM; Location: Hall C; "The tracer's biodistribution kinetics may differ substantially between 177Lu-DOTATATE in neuroendocrine neoplasms (NEN) and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), potentially demanding disease-specific imaging protocols. Optimal post-treatment imaging timing differs between disease entities. In NEN patients receiving 177Lu-DOTATATE, immediate post-infusion imaging (d0) captures peak lesion uptake most reliably, suggesting that same-day scanning should be considered. Conversely, in prostate cancer patients receiving 177Lu-PSMA, 24-hour imaging (d1) appears to be the optimal time point, consistent with the slower tumor internalization kinetics of PSMA-targeted agents."
Castration-Resistant Prostate Cancer • Endocrine Cancer • Genito-urinary Cancer • Neuroendocrine Neoplasm • Prostate Cancer • Solid Tumor
|
|
J. Koutsikos 1; I. Papantoniou 1; G. Thiveos 1; A. Kokkini -Paschou 1, 2; M. Stathopoulou 1; V. Pantzou 1; S. Bacalis 2; T. Petropoulos 1; E. Skoura 1; A. Velidaki 3; I. Datseris 1
|